Obesity drugs deemed inefficient as consumers pay higher prices for short-term solutions

17 Jul 2023 — Two-thirds of obesity medication GLP-1a (glucagon-like peptide-1 agonist) consumers stop taking the medication within a year, according to a new report by Prime Therapeutics. 

The report details that the average annual cost of such drugs is US$19,657 for consumers, compared to the US$12,379 overall care cost for obese patients before taking the medication, an increase of 59%.